Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Remain at the forefront of Nanomedicine (without leaving the home or office)

Abstract:
ACCME accredited Webinar Series produced by UC San Diego NanoTumor Center

Sessions from Nov 20, 2009 - Feb 3, 2010

Remain at the forefront of Nanomedicine (without leaving the home or office)

La Jolla, Ca | Posted on November 25th, 2009

Nanotechnology-the science and engineering of manipulating matter at the molecular scale to create devices with novel chemical, physical and biological properties-has the potential to radically change how we diagnose and treat diseases such as cancer. Nanomedicine is the medical application of nanoscience methods, tools and materials for the benefit of the patient. Great progress is moving nano-based therapies into the clinic and many more are in development.

This webinar series is designed to address the particularly growing need for knowledge of how nanotechnology will contribute to the evolution of medicine and in oncology. This six module series is the first of many to cover topics ranging from introduction and foundation lectures to clinically relevant nanotechnology applications that impact drug delivery, diagnostic sensing, therapeutics, imaging, surgery and more. We invite you to subscribe to our webinar notification list to help you stay on the leading edge of nanomedicine as we develop additional nanomedicine modules.

Why Participate?

* Develop knowledge about the impact of nanotechnology in medicine
* Learn about new technologies and how they are being applied
* Gain insight on resources available today
* Identify and understand various nanomedicine approaches to disease
* Expand your network and create alliances with nanotechnology experts
* Licensed providers can earn up to 6.0 AMA PRA Category 1 Credits™ for webinar module series (1 per module).

Who will benefit:

Physicians, Pharmacists, Nurses, Therapists, Health Providers, Technologists, Researchers , R&D personnel in all areas of science, Executives, Directors, Business Development professionals who:

* want to learn about existing and future applications using nanotechnology in the medical field for cancer treatment
* are in the medical field, nanomaterials field, pharmaceutical or biotechnology field
* work with companies who supply to nanomedical firms
* have an interest in the future of medicine

####

About UC San Diego School of Medicine
The Mission of the University of California, San Diego Continuing Medical Education (UCSD CME) is to provide needs based education for physicians and health care providers to improve knowledge, competence and performance and enable the optimum provision of health care.

We are committed to continual improvement of our educational mission by researching current adult education and CME literature, participation in national organizations committed to improving CME, and implementation of innovative and creative programming that may further our mission.

The faculty at the UCSD School of Medicine are exceptionally talented, motivated and eager to share their knowledge and expertise through continuing medical education.

For more information, please click here

Contacts:
Webinar Inquiries? Email:

Copyright © UC San Diego School of Medicine

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

ANU invention to inspire new night-vision specs December 7th, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016

In IEDM 2016 Keynote, Leti CEO Says ‘Hyperconnectivity’, Human-focused Research and the IOT Promise Profound, Positive Changes December 7th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Announcements

ANU invention to inspire new night-vision specs December 7th, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016

In IEDM 2016 Keynote, Leti CEO Says ‘Hyperconnectivity’, Human-focused Research and the IOT Promise Profound, Positive Changes December 7th, 2016

Events/Classes

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

In IEDM 2016 Keynote, Leti CEO Says ‘Hyperconnectivity’, Human-focused Research and the IOT Promise Profound, Positive Changes December 7th, 2016

IEDM: Leti CEO Marie Semeria to Give Opening-day Keynote on Impact of ‘Hyperconnectivity’ and IoT: Speech to Portray Key Role Nonprofit Research and Technology Organizations Play in Making Technology More Efficient and Ensuring Safety and Security November 29th, 2016

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project